Pfizer's Inlyta gets NICE nod, but Dendreon's Provenge doesn't; Lilly chief maintains stance against megamergers;

@FiercePharma: ICYMI yesterday: Serum Institute and Bharat Biotech race to get swine flu vaccines back on the market. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: In case you missed our newest special: Top 10 drug brands by payments to doctors. Report | Follow @CarlyHFierce

> Pfizer's ($PFE) kidney cancer drug Inlyta won backing from British cost-effectiveness watchdogs, but Provenge, the Dendreon ($DNDN) med recently purchased by Valeant Pharmaceuticals ($VRX), wasn't so lucky. Report

> Eli Lilly ($LLY) CEO John Lechleiter maintains that big mergers are bad for pharma companies, and says he believes Lilly is immune to a hostile takeover. Report

> British doctors called on health officials to favor off-label use of the Roche ($RHHBY) cancer drug Avastin as an eye treatment, over the more expensive Lucentis, marketed in Europe by Novartis ($NVS). Report

> Biosimilar versions of the top-selling anti-inflammatory Remicade have rolled out in Europe. Report

Medical Device News

@FierceMedDev: Reuters: Boston Scientific close to $2B deal for Endo's AMS device unit. Report | Follow @FierceMedDev

@VarunSaxena2: From my med tech M&A special report: Zimmer swallowing up Biomet, leading to chain of other deals. More | Follow @VarunSaxena2

@EmilyWFierce: Get this week's ed. of FierceDiagnostics here, feat. 23andMe, $RHHBY and a new collaboration for Alzheimer's Dx. Newsletter | Follow @EmilyWFierce

> FDA in midst of updating endoscope labels implicated in 'superbug' infections. Report

> FDA weighs in on Intuitive Surgical recall of da Vinci vessel sealer due to inadequate grasping. More

Biotech News

@FierceBiotech: Little Neos gets a $20M bankroll to prep ADHD drugs for FDA review. News | Follow @FierceBiotech

@JohnCFierce: Top 10 drug brands by payments to doctors, from the FiercePharma Marketing team. Special report | Follow @JohnCFierce

@DamianFierce: Hey so @FierceBiotech has a podcast now, and you can listen online. Listen | Follow @DamianFierce

> Can Neil Woodford reignite the U.K.'s taste for biotech investments? More

> Takeda's betting on its pipeline to spur a long-awaited turnaround. Item

> Hospira and Celltrion storm the EU with biosimilars of J&J's Remicade. Article

Drug Delivery News

> OncoSec's intratumoral delivery platform to be tested on new partner's cancer candidates. Report

> MIT team injects drug-carrying hydrogel that 're-heals' in the body. Story

> WHO adopts new safety needle policy, calling smart syringes an 'urgent priority.' Article

> Prometheon touts its transdermal delivery system for large molecules, prepares to launch hair growth gel. Item

> FDA agrees to review Endo Pharmaceutical's inside-the-cheek pain drug. News

Diagnostics News

> Israeli colon capsule maker reels in $24M in IPO and private placement. More

> Roche, BioMed X to jointly run diagnostics incubator in Germany. Article

> Foundation Medicine rides tailwinds of successful Q4 2014. Item

> Department of Defense gives contractor $14.8M to test so-called Sample-to-Sequence system. Report

> 23andMe scores FDA OK to market genetic carrier test direct to consumers. News

Pharma Marketing News

> Can Pfizer's new breast cancer med really cruise to $4B and beyond? Article

> Shire's Vyvanse brand team draws fire for aggressive binge-eating push. More

> British doctors lobby NHS to use cheap Avastin over Lucentis in AMD. Report

> With peglispro shunted aside, Lilly could go full-tilt after Lantus. Story

> Valeant to keep specialty Salix reps, but it's eyeing primary care for potential cuts. Article

And Finally... A study that paid patients to take their HIV meds essentially failed, scientists said. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.